Last edition
News about "Harbour BioMed gMG Treatment"
China Approves Harbour BioMed's Batoclimab for Myasthenia Gravis
Harbour BioMed has received China NMPA approval of Batoclimab Injection (subcutaneous injection) for the treatment of generalised Myasthenia Gravis.
Harbour BioMed GMG Treatment | 26/10/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members